{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-041544","form_type":"8-K","ticker":"IRD","cik":"0001228627","company_name":"Opus Genetics, Inc.","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.985036+00:00","generated_at":"2026-05-16T20:56:06.748808+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Opus Genetics Q3 net loss $17.5M; cash >$50M; LCA5 gene therapy gains FDA RMAT","bullets":["Q3 net loss of $17.5M ($0.25/sh) vs $7.5M ($0.29/sh) in prior year; revenue $3.1M from Viatris collaboration.","Cash $30.8M at Sep 30; raised $23M post-quarter; total >$50M expected to fund into H2 2027.","Positive LCA5 data: 3-month pediatric and 18-month adult gains in cone-mediated vision; FDA RMAT meeting supports accelerated approval pathway.","BEST1 gene therapy trial recruiting; initial data Q1 2026. Phentolamine sNDA for presbyopia planned by year-end 2025.","Non-dilutive funding: $1.6M from RDH12 Alliance and $2M from Retinal Degeneration Fund for MERTK program."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-041544","json":"https://secwatch.observer/filing/0001140361-25-041544.json","markdown":"https://secwatch.observer/filing/0001140361-25-041544.md","text":"https://secwatch.observer/filing/0001140361-25-041544.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1228627/000114036125041544/0001140361-25-041544-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1228627/000114036125041544/ef20058670_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:56:06.748808+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}